Eric Assenat

857 total citations
3 papers, 25 citations indexed

About

Eric Assenat is a scholar working on Oncology, Surgery and Neurology. According to data from OpenAlex, Eric Assenat has authored 3 papers receiving a total of 25 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 1 paper in Surgery and 1 paper in Neurology. Recurrent topics in Eric Assenat's work include Neuroblastoma Research and Treatments (1 paper), Hepatitis C virus research (1 paper) and Colorectal Cancer Treatments and Studies (1 paper). Eric Assenat is often cited by papers focused on Neuroblastoma Research and Treatments (1 paper), Hepatitis C virus research (1 paper) and Colorectal Cancer Treatments and Studies (1 paper). Eric Assenat collaborates with scholars based in France. Eric Assenat's co-authors include Jean‐Charles Nault, Manon Allaire, Mohamed Bouattour, Boris Guiu, Harry Sokol, Jean‐Marie Péron, Philippe Merle, Karine Le Malicot, Jean‐Frédéric Blanc and David Tougeron and has published in prestigious journals such as Journal of Clinical Oncology, Digestive and Liver Disease and Nature Cancer.

In The Last Decade

Eric Assenat

3 papers receiving 25 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Assenat France 3 17 12 7 7 6 3 25
Yurii Ostapenko Ukraine 2 11 0.6× 12 1.0× 5 0.7× 5 0.7× 7 1.2× 4 23
Friedrich Sinner Germany 2 17 1.0× 29 2.4× 14 2.0× 4 0.6× 3 0.5× 3 37
Ankit Rao United Kingdom 3 32 1.9× 9 0.8× 6 0.9× 11 1.6× 8 1.3× 16 49
Martin Karamanliev Bulgaria 3 15 0.9× 5 0.4× 5 0.7× 6 1.0× 15 26
Brenda Hernandez Spain 2 15 0.9× 26 2.2× 16 2.3× 6 0.9× 3 0.5× 2 44
Guoliang Shao China 3 16 0.9× 28 2.3× 10 1.4× 6 1.0× 4 44
Cosmas Rinaldi Adithya Lesmana Indonesia 3 10 0.6× 14 1.2× 17 2.4× 3 0.4× 5 0.8× 13 28
Cuncai Zhou China 2 15 0.9× 21 1.8× 6 0.9× 8 1.3× 3 30
Susan Caird Australia 3 9 0.5× 6 0.5× 4 0.6× 4 0.7× 9 19
Igor Andrašina Slovakia 5 12 0.7× 12 1.0× 12 1.7× 3 0.4× 7 1.2× 12 54

Countries citing papers authored by Eric Assenat

Since Specialization
Citations

This map shows the geographic impact of Eric Assenat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Assenat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Assenat more than expected).

Fields of papers citing papers by Eric Assenat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Assenat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Assenat. The network helps show where Eric Assenat may publish in the future.

Co-authorship network of co-authors of Eric Assenat

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Assenat. A scholar is included among the top collaborators of Eric Assenat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Assenat. Eric Assenat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

3 of 3 papers shown
1.
Cousin, Sophie, Jean‐Philippe Guégan, Lola‐Jade Palmieri, et al.. (2025). Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis. Nature Cancer. 6(4). 584–594. 4 indexed citations
2.
Merle, Philippe, Jean‐Frédéric Blanc, Julien Edeline, et al.. (2023). Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial. Digestive and Liver Disease. 55(4). 464–470. 18 indexed citations
3.
Assenat, Eric, Julien Fraisse, Emmanuelle Samalin, et al.. (2018). A multicenter phase Ib-IIR trial assessing the activity of regorafenib combined with modified gemcitabine: Oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer (aBTC).. Journal of Clinical Oncology. 36(15_suppl). e16134–e16134. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yurii Ostapenko Breakdown of academic impact, for papers by Friedrich Sinner Breakdown of academic impact, for papers by Ankit Rao Breakdown of academic impact, for papers by Martin Karamanliev Breakdown of academic impact, for papers by Brenda Hernandez Breakdown of academic impact, for papers by Guoliang Shao Breakdown of academic impact, for papers by Cosmas Rinaldi Adithya Lesmana Breakdown of academic impact, for papers by Cuncai Zhou Breakdown of academic impact, for papers by Susan Caird Breakdown of academic impact, for papers by Igor Andrašina
Rankless by CCL
2026